Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006389 · ClinicalTrials.gov registry record · Phase 2
Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00006389: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00006389 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006389, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of bryostatin 1 and cisplatin in treating patients who have metastatic or unresectable stomach cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bryostatin 1 may increase the effectiveness of cisplatin by making tumor cells more sensitive to the drug. Combining cisplatin with bryostatin 1 may kill more tumor cells.
Interventions
- OTHER laboratory biomarker analysis
- DRUG cisplatin
- DRUG bryostatin 1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2000-10 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006389
The ClinicalTrials.gov registry entry for NCT00006389 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00006389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006389 about?
NCT00006389 is a clinical study titled "Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer". Phase II trial to study the effectiveness of bryostatin 1 and cisplatin in treating patients who have metastatic or unresectable stomach cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bryostatin 1 may increase the effectiveness of...
What is the current status of trial NCT00006389?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2000-10. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00006389?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cisplatin (DRUG), bryostatin 1 (DRUG).
Who is sponsoring clinical trial NCT00006389?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.